This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings

For the quarter ended June 2026, Zai Lab Limited Unsponsored ADR (ZLAB) reported revenue of $106.31 million, down 3.3% over the same period last year. EPS came in at -$0.46, compared to -$0.37 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $106.33 million, representing a surprise of -0.01%. The company delivered an EPS surprise of +19.3%, with the consensus EPS estimate being -$0.57.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Zai Lab Limited performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Product Revenue- ZEJULA: $32.08 million versus the two-analyst average estimate of $32.29 million. The reported number represents a year-over-year change of -21.8%.
Product Revenue- OPTUNE: $12.2 million versus the two-analyst average estimate of $12.6 million. The reported number represents a year-over-year change of -1.2%.
Product Revenue- QINLOCK: $9.59 million versus the two-analyst average estimate of $8.59 million. The reported number represents a year-over-year change of +12.4%.
Product Revenue- NUZYRA: $17.1 million compared to the $17.36 million average estimate based on two analysts. The reported number represents a change of +19.6% year over year.
Collaboration revenue: $0.56 million versus the two-analyst average estimate of $-0.67 million.
Product Revenue- XACDURO: $7.96 million versus the two-analyst average estimate of $9.24 million.
Product Revenue- AUGTYRO: $2.21 million compared to the $1.84 million average estimate based on two analysts.
Product Revenue, net: $105.75 million compared to the $106.99 million average estimate based on two analysts.
Product Revenue- VYVGART: $23.87 million compared to the $21.49 million average estimate based on two analysts. The reported number represents a change of -9.9% year over year.

View all Key Company Metrics for Zai Lab Limited here>>>

Shares of Zai Lab Limited have returned -7% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.

See them now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Zai Lab Limited Unsponsored ADR (ZLAB): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research